Back to Search Results
Image Place holder

Yoly Pina, MD

★★★★★
★★★★★
4.7 (59 ratings)
Specialty: Neuro Oncology
Sub Specialty: Neuro-Oncology
Program: Neuro-Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Brain Cancer, Glioblastoma, Meningioma, Neurofibromatosis

Dr. Piña earned her M.D. from the University of South Florida, Morsani College of Medicine, where she also completed her Residency in Neurology.  She recently completed a Neuro-Oncology Fellowship at Moffitt Cancer Center. Dr. Piña has over 40 peer-reviewed publications, has written Investigator Initiated Trials (IIT), and submitted a grant during her Fellowship at Moffitt.  Her main clinical and translational research focus will be to develop a program and specialization in “onco-neurology.”  This program will seek to understand, prevent and treat the neurologic complications of immunotherapies such as CAR-T cell Therapy and Immune Checkpoint Inhibitors.  Her other clinical and translational research interests include central nervous system primary and metastatic tumors.  


Education & Training

Board Certification:

  • Neurology - Neuro-Oncology

Fellowship:

  • Moffitt Cancer Center - NeuroOncology

Residency:

  • University of South Florida - Neurology

Medical School:

  • USF Morsani College of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kareem SS, Viswanathan N, Sahebjam S, Tran ND, Gatewood T, Tobon K, Baz R, Piña Y, Shain KH, Mokhtari S. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma. Onco Targets Ther. 2022 Sep.15:953-962. Pubmedid: 36097632. Pmcid: PMC9464026.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
  • Liu JKC, Kang R, Bilenkin A, Prorok R, Whiting J, Patel KB, Beer-Furlan A, Naso C, Rogers A, Castro XB, Peguero E, Mokhtari S, Tran N, Etame A, Pina Y, Spiess PE, Forsyth P, Vogelbaum MA. Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. J Neurooncol. 2022 Nov.160(2):517-525. Pubmedid: 36367630. Pmcid: PMC9651094.
  • Piña Y, Yadugiri S, Yeboa DN, Ferguson SD, Forsyth PA, Oliva ICG. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma. Curr Oncol Rep. 2022 Jan.24(1):43-54. Pubmedid: 35059999.
  • Piña Y, Gramatzki D, Forsyth P, Lee EQ, Le Rhun E. Leptomeningeal Disease. Hematol Oncol Clin North Am. 2022 Feb.36(1):189-215. Pubmedid: 34756800.
  • Lowe SR, Wang CP, Brisco A, Whiting J, Arrington J, Ahmed K, Yu M, Robinson T, Oliver D, Etame A, Tran N, Beer Furlan A, Sahebjam S, Mokhtari S, Piña Y, Macaulay R, Forsyth P, Vogelbaum MA, Liu JKC. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neurooncol. 2022 Aug.24(8):1307-1317. Pubmedid: 35092434. Pmcid: PMC9340645.
  • Mills MN, King W, Soyano A, Pina Y, Czerniecki BJ, Forsyth PA, Soliman H, Han HS, Ahmed KA. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. J Neurooncol. 2022 Apr.157(2):249-269. Pubmedid: 35244835.
  • Alvarez-Breckenridge C, Remon J, Piña Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, Brastianos PK. Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. Am Soc Clin Oncol Educ Book. 2022 Apr.42:1-19. Pubmedid: 35522917.
  • Zemina K, Piña Y, Malafronte P, Suresh N, Hurst R. Spongiform leukoencephalopathy: A unique case of biopsy confirmed leukoencephalopathy secondary to toxic, non-inflammatory exposure. SAGE Open Med Case Rep. 2021 Sep.9. Pubmedid: 34484793. Pmcid: PMC8414607.
  • Verma N, Jaffer M, Pina Y, Peguero E, Mokhtari S. Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis. Cureus. 2021 Jul.13(7):e16337. Pubmedid: 34395120. Pmcid: PMC8357079.
  • Fusco MJ, Piña Y, Macaulay RJ, Sahebjam S, Forsyth PA, Peguero E, Walko CM. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas. Cancer Control. 2021 Jan.28. Pubmedid: 34620004. Pmcid: PMC8506147.
  • Wilkes JG, Patel A, McClure E, Pina Y, Zager JS. Developments in therapy for brain metastases in melanoma patients. Expert Opin Pharmacother. 2021 Aug.22(11):1443-1453. Pubmedid: 33688795.
  • Piña Y, Evernden BR, Khushalani N, Margolin K, Tawbi H, Tran ND, Macaulay R, Forsyth P, Peguero E. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. SAGE Open Med Case Rep. 2021 Aug.9. Pubmedid: 34457306. Pmcid: PMC8392782.
  • Piña Y, Fusco MJ, Macaulay RJ, Walko CM, Peguero E, Evernden BR, Smalley KS, Forsyth P. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma. J Neurol. 2020 Mar.267(3):783-790. Pubmedid: 31748891. Pmcid: PMC7035305.
  • Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol. 2012 May.6:817-830. Pubmedid: 22701083. Pmcid: PMC3373226.
  • Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophth Vis Sci. 2012 Feb.53(2):996-1002. Pubmedid: 22266512. Pmcid: PMC3317436.
  • Piña Y, Decatur C, Murray T, Houston S, Gologorsky D, Cavalcante M, Cavalcante L, Hernandez E, Celdran M, Feuer W, Lampidis T. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol. 2011 Mar.5:337-343. Pubmedid: 21468343. Pmcid: PMC3065577.
  • Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Schefler AC, Murray TG. Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. Invest Ophth Vis Sci. 2011 Jul.52(8):5359-5368. Pubmedid: 21571674. Pmcid: PMC3176059.
  • Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol. 2011 Jan.5:129-137. Pubmedid: 21339806. Pmcid: PMC3037041.
  • Boutrid H, Wolfe SQ, Murray TG, Pina Y, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA. Bilateral orbital vasculature alterations after systemic chemotherapy and external beam radiation therapy treatment of advanced retinoblastoma: implications for intraarterial chemotherapy management. Retin Cases Brief Rep. 2011 Apr.5(2):124-127. Pubmedid: 25389879.
  • Piña Y, Boutrid H, Murray TG, Wolfe SQ, Schefler AC, Houston SK, Moftakhar R, Fernandes CE, Reichbach J, Aziz HA, Markoe AM, Aziz-Sultan MA. Ophthalmic vasculature alterations following systemic chemotherapy and periocular Carboplatin treatment of advanced retinoblastoma. J Pediat Ophth Strab. 2010 Sep.47 Online:e1-e5. Pubmedid: 20886809.
  • Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One. 2010 Oct.5(10):e13699. Pubmedid: 21060881. Pmcid: PMC2965179.
  • Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME. Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophth Vis Sci. 2010 May.51(5):2671-2677. Pubmedid: 20053982. Pmcid: PMC2868494.
  • Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol. 2010 May.4:519-524. Pubmedid: 20535228. Pmcid: PMC2879353.
  • Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophth Vis Sci. 2010 Jun.51(6):2860-2864. Pubmedid: 20107171. Pmcid: PMC2891454.
  • Piña Y, Houston SK, Murray TG, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophth Vis Sci. 2010 Dec.51(12):6149-6156. Pubmedid: 20702830. Pmcid: PMC3055749.
  • Gologorsky D, Schefler AC, Ehlies FJ, Raskauskas PA, Pina Y, Williams BK, Murray TG. Clinical imaging and high-resolution ultrasonography in melanocytoma management. Clin Ophthalmol. 2010 Aug.4:855-859. Pubmedid: 20714362. Pmcid: PMC2921292.
  • Aziz HA, Boutrid H, Murray TG, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. Retina. 2010 Apr.30(4 Suppl):S63-S65. Pubmedid: 20224464.
  • Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG. Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophth Vis Sci. 2009 Mar.50(3):1020-1024. Pubmedid: 18952925.
  • Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophth Vis Sci. 2009 Dec.50(12):5537-5543. Pubmedid: 19578014.
  • Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME. Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. Ophthalmic Res. 2009 Apr.41(3):160-169. Pubmedid: 19321938. Pmcid: PMC3713740.
  • Jockovich ME, Piña Y, Alegret A, Cebulla C, Feuer W, Murray TG. Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy. Retina. 2008 Mar.28(3 Suppl):S81-S86. Pubmedid: 18317352.
  • Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ, Cebulla CM. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophth Vis Sci. 2008 Jul.49(7):2799-2805. Pubmedid: 18326690.
  • Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, Murray TG. Basic fibroblast growth factor impact on retinoblastoma progression and survival. Invest Ophth Vis Sci. 2008 Dec.49(12):5215-5221. Pubmedid: 18614803. Pmcid: PMC4139118.
  • Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG. Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma. Open Ophthalmol J. 2008 Apr.2:62-67. Pubmedid: 19517030. Pmcid: PMC2694596.
  • Jockovich ME, Bajenaru ML, Piña Y, Suarez F, Feuer W, Fini ME, Murray TG. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest Ophth Vis Sci. 2007 Jun.48(6):2476-2482. Pubmedid: 17525173.
  • Jockovich ME, Suarez F, Alegret A, Piña Y, Hayden B, Cebulla C, Feuer W, Murray TG. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Invest Ophth Vis Sci. 2007 Dec.48(12):5371-5376. Pubmedid: 18055783.
  • Espinosa-Heidmann DG, Reinoso MA, Pina Y, Csaky KG, Caicedo A, Cousins SW. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res. 2005 Mar.80(3):369-378. Pubmedid: 15721619.
  • Caicedo A, Espinosa-Heidmann DG, Hamasaki D, Piña Y, Cousins SW. Photoreceptor synapses degenerate early in experimental choroidal neovascularization. J Comp Neurol. 2005 Mar.483(3):263-277. Pubmedid: 15682400.
  • Caicedo A, Espinosa-Heidmann DG, Piña Y, Hernandez EP, Cousins SW. Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp Eye Res. 2005 Jul.81(1):38-47. Pubmedid: 15978253.

Grants

Title: Feasibility of expending autologous tumor infiltrating lymphocytes (TIL) from patients with leptomeningeal disease from melanoma.
Sponsor: Moffitt Cancer Center
PI: Pina, Y., CO-PI: Pilon-Thomas, S.

Patient Comments
Overall Satisfaction
4.7
★★★★★
★★★★★

59 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments